Financial Performance - The company reported a net loss of approximately HKD 136,015,000 for the fiscal year 2021 and an operating cash outflow of about HKD 15,164,000[4]. - As of December 31, 2021, the company had current liabilities and total liabilities of approximately HKD 232,439,000 and HKD 98,942,000, respectively[4]. - The company's bank balances and cash, along with pledged bank deposits, amounted to approximately HKD 66,634,000 and HKD 1,190,000, respectively, against borrowings and payables of approximately HKD 263,567,000 and HKD 3,967,000[4]. Management Actions - Management has implemented measures to improve financial conditions, including extending repayment terms with lenders and controlling operating costs to enhance cash flow[6]. - The company is considering alternative financing arrangements, including equity and debt financing, to alleviate liquidity pressure and improve cash flow[10]. - Management acknowledges the uncertainties related to cash flow generation and the impact of the COVID-19 pandemic on business operations[7]. Future Outlook - The company believes it will have sufficient working capital for at least 12 months from December 31, 2021, based on successful implementation of its measures[7]. - The board of directors believes that the company will have sufficient working capital to meet its financial obligations for the next twelve months[11]. - The company aims to eliminate the audit opinion by successfully executing its plans, including obtaining alternative financing[11]. Audit and Compliance - The audit committee has reviewed the management's actions to address the audit opinion and supports the management's position regarding the company's ability to continue as a going concern[9].
瀛晟科学(00209) - 2021 Q4 - 年度财报